Sign in
Stories
Addex Therapeutics Meeting
Share
Addex Therapeutics to Participate in Bio...
Addex Therapeutics: Financial Updates an...
ADOCIA Files 2023 Registration Document
Addex Therapeutics Enters ADS Offering A...
Genetic Technologies Closes Funding Roun...
Overview
API
Addex Therapeutics has called for an Extraordinary General Meeting to discuss various items, including the election of new board members and the implementation of article 20 of the company's articles of association. The meeting will focus on the lead drug candidate, ADX71149, which is in a Phase 2 clinical trial for treating epilepsy, as well as the company's licensed GABAB PAM program for substance use disorder and a broad preclinical pipeline.
Ask a question
How might the progress of ADX71149 in the clinical trial impact the company's reputation and future prospects?
What are the key challenges and opportunities in the development of Addex Therapeutics' broad preclinical pipeline?
What are the potential implications of the upcoming Extraordinary General Meeting for Addex Therapeutics?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Aug 2023
Sep 2023
Oct 2023
Coverage